-
EP4004558
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4004558
| EP4004558 - METHODS OF QUANTIFYING FRATAXIN AND FRATAXIN FUSION PROTEINS [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 14.06.2024 Database last updated on 16.11.2024 | |
| Former | Request for examination was made Status updated on 29.04.2022 | ||
| Former | The international publication has been made Status updated on 05.02.2021 | ||
| Former | unknown Status updated on 02.09.2020 | Most recent event Tooltip | 25.10.2024 | Change: Despatch of examination report + time limit | Applicant(s) | For all designated states Larimar Therapeutics, Inc. Three Bala Plaza East, Suite 506 Bala Cynwyd, PA 19004 / US | For all designated states The United States of America, as represented by the Secretary, Department of Health and Human Services The Office of Technology Transfer National Institutes of Health 6011 Executive Boulevard Suite 325, MSC 7660 Bethesda, MD 20892-7660 / US | [2022/22] | Inventor(s) | 01 /
BETTOUN, Joan David 8106 Cadwalader Avenue Elkins Park, PA 19027 / US | 02 /
WAGNER, Erik Johan 406 Gary Ct. Sterling, VA 20164 / US | 03 /
XU, Xin 9700 Beman Woods Way Potomac, MD 20854 / US | 04 /
MESS, Jean-Nicholas 2097 rue des Becs-Scies Laval, Quebec H7L 5N5 / CA | 05 /
WANG, Amy Qiu 18417 McKernon Way Poolesville, MD 20837 / US | [2022/22] | Representative(s) | Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE | [2022/22] | Application number, filing date | 20761369.6 | 29.07.2020 | [2022/22] | WO2020US44118 | Priority number, date | US201962880068P | 29.07.2019 Original published format: US 201962880068 P | US201962936293P | 15.11.2019 Original published format: US 201962936293 P | [2022/22] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2021021964 | Date: | 04.02.2021 | Language: | EN | [2021/05] | Type: | A2 Application without search report | No.: | EP4004558 | Date: | 01.06.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 04.02.2021 takes the place of the publication of the European patent application. | [2022/22] | Search report(s) | International search report - published on: | EP | 18.03.2021 | Classification | IPC: | G01N33/68 | [2022/22] | CPC: |
G01N33/6848 (EP,IL,KR,US);
A61K38/00 (KR);
G01N33/6896 (EP,IL);
C07K2319/03 (KR);
C07K2319/07 (KR)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/22] | Title | German: | VERFAHREN ZUR QUANTIFIZIERUNG VON FRATAXIN UND FRATAXINFUSIONSPROTEINEN | [2022/22] | English: | METHODS OF QUANTIFYING FRATAXIN AND FRATAXIN FUSION PROTEINS | [2022/22] | French: | PROCÉDÉS DE QUANTIFICATION DE PROTÉINES DE FUSION DE FRATAXINE ET DE FRATAXINE | [2022/22] | Entry into regional phase | 25.02.2022 | National basic fee paid | 25.02.2022 | Designation fee(s) paid | 25.02.2022 | Examination fee paid | Examination procedure | 25.02.2022 | Examination requested [2022/22] | 25.02.2022 | Date on which the examining division has become responsible | 04.10.2022 | Amendment by applicant (claims and/or description) | 26.06.2024 | Despatch of a communication from the examining division (Time limit: M06) | Fees paid | Renewal fee | 27.07.2022 | Renewal fee patent year 03 | 27.07.2023 | Renewal fee patent year 04 | 29.07.2024 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [I]US2017320968 (TREMBLAY JACQUES P [CA], et al); |